Development of biosimilars has expanded patients’ treatment options by offering innovative medicine at lower costs than traditional biologics. So why are some nations slow to adopt biosimilars?

Physicians across Latin America are coming together to discuss a timely topic: what access to biosimilars means to their patients.

New medical guidelines often come with an intrinsic irony.

Weeks shy of the annual European Society of Cardiology Congress, new data from the United States shed light on the importance of cardiovascular prevention.

A recent survey of Europeans with gout offers a startling reminder that stigma can have real medical consequences.

The United Kingdom’s Brexit saga has captured the attention of the world.  But it’s also sparked concerns among British patients, researchers and health care advocates, who are asking: How will health research and innovation fare after the UK severs ties with the European Union? Research on cardiovascular disease provides an apt example.  According to the … Continued

When it comes to shared medical decision-making, European patients with rheumatoid arthritis are open to ideas.   A recent patient questionnaire from the European Alliance for Patient Access revealed that patients don’t always find it easy to talk with their doctor or nurse about their symptoms, treatment and quality of life with rheumatoid arthritis.  And … Continued

Central and South American governments should consider new policies that support innovation in health care and improve patient access, according to results from a survey recently conducted by the Global Alliance for Patient Access.